It is the combined effects of BAY1082439 on Pten-null cancer cells and immune cells in the tumor microenvironment leads to tumor burden reduction as well as tumor-associated CD8+ T cell activation, clonal expansion and infiltration into the tumor acini. This evidence concerns the gene CD8A and neoplasm.